IONIS PKKRx

Drug Profile

IONIS PKKRx

Alternative Names: IONIS-PKKRx; ISIS-PKKRx

Latest Information Update: 24 Dec 2015

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hereditary angioedema

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 24 Feb 2015 Isis Pharmaceuticals plans to initiate a phase II trial in Hereditary angioedema
  • 24 Feb 2015 Efficacy and adverse events data from a phase I trial in Healthy volunteers released by Isis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top